Prescription drug · BLA
Steqeyma (ustekinumab-stba) NDC 72606-029
Ustekinumab 130 mg/26mL · Injection, Solution · Intravenous · CELLTRION USA, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 72606-029-01 | 72606002901 | 1 VIAL, SINGLE-USE in 1 CARTON (72606-029-01) / 26 mL in 1 VIAL, SINGLE-USEMarketed from Mar 12, 2025 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Steqeyma
- Generic name (nonproprietary)
- ustekinumab-stba
- Active ingredients
- Ustekinumab — 130 mg/26mL
- Dosage form
- Injection, Solution
- Route
- Intravenous
- Labeler
- CELLTRION USA, Inc.
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761338
- Marketing start
- Listing expires
- Other FDA classes
- Interleukin-12 Antagonists (Mechanism)Interleukin-23 Antagonists (Mechanism)
- Identifiers
- Product ID 72606-029_41fbe62e-a448-4c10-89fb-197959983091SPL ID 41fbe62e-a448-4c10-89fb-197959983091SPL set ID 66085e17-e3f2-4196-8c81-87448e804b0cRxCUI 2700393, 2700400, 2700404, 2700409, 2700411, 2700412, 2740798, 2740800UNII FU77B4U5Z0UPC 0372606028017
- Pharmacologic class
- Interleukin-12 Antagonist; Interleukin-23 Antagonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N472606002901followed by a unit qualifier and the quantityPackage 72606-0029-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
1. INDICATIONS AND USAGE STEQEYMA is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) moderately to severely active Crohn's disease (CD) . ( 1.3 ) moderately to severely active ulcerative colitis. ( 1.4 ) Pediatric patients 6 years and older with: moderate to severe plaque psoriasis (PsO), who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) 1.1. Plaque Psoriasis (PsO) STEQEYMA is indicated for the treatment of adults and pediatric patients 6 ye…
Excerpt only. Read the full label for complete information.
Other NDCs under BLA 761338
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Steqeymaustekinumab-stba | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | CELLTRION USA, Inc. | 72606-027 |
| Steqeymaustekinumab-stba | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | CELLTRION USA, Inc. | 72606-028 |
| Steqeymaustekinumab-stba | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | CELLTRION USA, Inc. | 72606-060 |